China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan.
    With all-out efforts, SINOPHARM is promoting the construction of four major platforms – the integrated distribution and logistics platform, the integrated manufacturing and R&D industrial platform, the integrated globally operational platform and highly efficient control and integration services platform to advance the development of the ten business cores of pharmaceutical logistics, distribution and delivery; medicine retail trade; bio-pharm; chemical pharmaceuticals; modern TCM; medical equipments; pharmaceutical import/export and overseas industry; chemical reagents and diagnosis reagents; medical scientific research and design; and pharmaceutical exhibitions, in order to form a complete central enterprise pharmaceutical and healthcare platform. SINOPHARM has achieved the economies of scale that spurring the exponential growth of the business performance. During Year 2003 and Year 2009, the sales revenue, gross profit and total assets of SINOPHARM grew at an annual average rate of 30.67%, 51.19% and 33.32% respectively. In China, by possessing the first-class manufacturers for medicines, vaccines and blood products, high-level R & D institutes, a country-wide distribution network, large-scale TCM plant bases and top pharmaceutical exhibitions, SINOPHARM has completed its industrial chain. Since 1980, SINOPHARM has cooperated with foreign global pharmaceutical companies and established 20 joint ventures including China Otsuka, SSPC, etc.; developed international technical cooperation projects with USA, Japan, France, UK, Germany, Italy and Republic of Korea etc.; built up bonds of trade and cooperation with more than 100 countries or regions. Those actions have effectively improved the manufacture and management level of pharmaceutical industry in China.
    Under the guide of the corporate conception of ‘Caring for life, attending to health’, SINOPHARM and its subsidiaries have always undertaken the responsibility of central reserve, allocation and supply of medicines, bio-tech products, traditional Chinese medicines and medical equipments for public health emergencies disasters and epidemics. In fighting against SARS in 2003, combating Sichuan Earthquake in 2008 and prevention and control of A H1N1 influenza in 2009, SINOPHARM played an important role in safeguarding the public health and maintaining community stability.
    SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA.
    SINOPHARM is aiming for annual sales revenue of 100 billion Yuan in 2012 and step into the Top 500 Global Corporations during the 12th Five Year Plan, in order to become an industry advanced central pharmaceutical and healthcare group with international competitive ability.